Parenteral Drugs (India)'s total inventories for the quarter that ended in Mar. 2022 was ₹10.27 Mil. Parenteral Drugs (India)'s average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was ₹5.14 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Parenteral Drugs (India)'s Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was ₹-438.61.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Parenteral Drugs (India)'s Days Inventory for the
three
months ended in Mar. 2022 was 26.67.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Parenteral Drugs (India)'s Inventory Turnover for the quarter that ended in Mar. 2022 was 3.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parenteral Drugs (India)'s Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.29.
Parenteral Drugs (India) (NSE:PDPL) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Parenteral Drugs (India)'s Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parenteral Drugs (India)'s Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Parenteral Drugs (India) Total Inventories Related Terms
Parenteral Drugs (India) Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parenteral Drugs (India) Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Parenteral Drugs (India) (NSE:PDPL) has a Total Inventories of ₹10.27 Mil as of Mar. 2022. The total amount of inventory as recorded on a company's balance sheet. View historical data for Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Total Inventories too high?
Parenteral Drugs (India)'s current Total Inventories is ₹10.27 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Total Inventories compare to ZTS and CTLT?
Parenteral Drugs (India)'s Total Inventories of ₹10.27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Total Inventories is ₹10.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Total Inventories of ₹10.27 Mil. The current Total Inventories is ₹10.27 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Total Inventories is ₹10.27 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score
Get the complete analysis for NSE:PDPL
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PDPL has been successfully added to your 
